In normotensive patients with acute symptomatic pulmonary embolism (PE), the effect of undiagnosed obstructive sleep apnea (OSA) on cardiovascular (CV) outcomes lacks clarity. The Prognostic Significance of Obstructive Sleep Apnea in Patients With Acute Symptomatic Pulmonary Embolism (POPE) study is a multicenter, observational study designed to prospectively assess the prognostic significance of concomitant OSA in hemodynamically stable outpatients with acute symptomatic PE. Adult patients with acute stable PE are eligible. Recruited patients undergo an overnight sleep study using a level III portable diagnostic device within 7 days (and preferably within 48 hours) of diagnosis of PE. The sleep tracings are analyzed by a certified sleep technologist and audited by a sleep physician, both of whom are blinded to other study data. The patients are divided into 2 groups based on apnea-hypopnea index (AHI): OSA (AHI ≥15) and non-OSA (AHI <15) groups. The study uses a composite of PE-related death, CV death, clinical deterioration requiring an escalation of treatment, or nonfatal CV events (recurrent venous thromboembolism, acute myocardial infarction, or stroke) within 30 days after the diagnosis of PE as the primary outcome. The projected sample size of 225 patients will provide 80% power to test the hypothesis that OSA will increase the primary outcome from 7% in the non-OSA group to 20% in the OSA group, with α ≤0.05. The trial results will be important to understand the burden and CV effects of OSA in PE patients.
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| INTRODUCTION
Acute pulmonary embolism (PE), a commonly diagnosed condition, has a morbidity and mortality rate that varies significantly by age, clinical presentation, and the presence of comorbid disease. [1] [2] [3] [4] [5] [6] In some cases, patients with PE may safely undergo treatment at home and avoid admission to a hospital. [7] [8] [9] However, some patients require immediate admission to an intensive care unit to prevent death. 10 The clinical course for a large proportion of patients will fall somewhere between these 2 extremes, making accurate risk stratification a critical component of the initial evaluation.
11,12
Obstructive sleep apnea (OSA) is an emerging cardiovascular (CV) risk factor that is present in about 9% to 15% of middle-aged adults. 13 OSA is characterized by recurrent episodes of complete or partial upper-airway obstruction due to the collapse of upperpharyngeal soft tissue during sleep, resulting in intermittent oxygen deprivation and sleep fragmentation. Sympathetic activation, production of vasoactive substances, and activation of inflammatory and procoagulant pathways contribute to CV pathogenesis, 14 including hypertension, coronary artery disease, stroke, and heart failure. A previous study suggested that untreated OSA is independently associated with subsequent cardiac and cerebrovascular events in patients undergoing percutaneous coronary intervention. 15 However, no studies have assessed the effect of undiagnosed OSA on CV outcomes in patients with acute symptomatic PE.
Therefore, the multicenter cohort Prognostic Significance of Obstructive Sleep Apnea in Patients With Acute Symptomatic Pulmonary Embolism (POPE) study aims to determine the association between OSA and the incidence of adverse CV outcomes in patients with acute symptomatic PE. We hypothesize that OSA is an independent risk factor for the development of major adverse CV events in PE patients. Results from the POPE study will advance the fundamental understanding of the burden and prognostic implications of OSA in patients with acute PE. In addition, this trial aims to validate the STOP-Bang score in a Spanish cohort of patients with acute symptomatic PE.
| METHODS

| Study design
POPE is a prospective, multicenter, observational cohort study designed by the authors and sponsored by Sociedad Española de Neumología y Cirugía Torácica (SEPAR) and Neumomadrid ( Figure 1 ).
The main objective of this study is to assess the prognostic significance of untreated OSA in hemodynamically stable outpatients with acute symptomatic PE. Secondary objectives of the study are to assess (1) the prevalence of undiagnosed OSA in normotensive patients with acute PE and (2) the association between OSA and the presence of right ventricular (RV) dysfunction and/or myocardial injury at the time of PE diagnosis. Additionally, we aim to validate the STOP-Bang questionnaire in this cohort. 16 The protocol and consent forms were approved by the institutional review board of each center.
| Setting
Patients undergo recruitment from the respiratory departments of 3 academic hospitals in Spain.
| Patients
The study aims to enroll consecutive outpatients with an objectively confirmed diagnosis of acute symptomatic PE. The study requires confirmation of the diagnosis of PE with a high-probability 
| OSA screening questionnaire
During the index hospitalization period for acute PE, recruited patients are approached to complete the STOP-Bang questionnaire and Epworth Sleepiness Scale (ESS) questionnaire ( Table 2 ). The STOP-Bang questionnaire is a validated screening tool to identify individuals at high risk for OSA. 16 It consists of 8 dichotomous 
| Overnight sleep study
The study schedules recruited patients for an overnight sleep study for use against in-laboratory polysomnography. The reported sensitivity and specificity are 100% and 70%, respectively. 22 The portable guidelines. 24 Patients diagnosed with central sleep apnea are excluded from the analyses.
| Transthoracic echocardiography
The study requires that patients undergo transthoracic echocardiog- 
| Study outcome measures
The study uses a composite of PE-related death, CV death, clinical deterioration requiring an escalation of treatment, or nonfatal CV events (recurrent venous thromboembolism, acute myocardial infarction, or stroke) within 30 days after the diagnosis of PE as the primary outcome. Investigators assess mortality using patient or proxy interviews and/or hospital chart review. An independent adjudication committee, whose members are blinded to initial prognostic test 
| Statistical analyses
We will use χ 2 or Fisher exact tests to compare categorical data between groups. We will use the Shapiro-Wilk test to assess continuous data for a normal distribution. We will use 2-tailed unpaired t tests to compare parametric continuous data between 2 unpaired groups, and we will use the Mann-Whitney U test for nonparametric data comparisons. We will use Cox proportional hazard models to evaluate the association between OSA and the outcome measures. A manual backward stepwise approach will be used to develop the multivariable models. In the full model, covariates determined a priori to be associated with mortality (ie, age, male sex, body mass index, SBP, heart rate, and arterial oxygen saturation) and covariates with imbalance between the groups at baseline will be considered for inclusion. Variables that show evidence of confounding (ie, the coefficient of the variable group changes by >10% when removing that variable from the full model) for the effect of reperfusion on the outcome undergoing analysis will not be removed from the model. Specific candidate variables will be forced, 1 at a time, into the full model to assess their effects.
We will also calculate sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratios, and area under the receiver operating characteristic curve of a STOP-Bang score ≥ 3 for prediction of moderate to severe OSA.
| Missing data
Investigators will impute variables' missing data by using the multiple imputations by chained equation method, 29 which will result in 10 imputed data sets. We will independently analyze each of the 10 data sets. We will average estimates of the variables to give a single mean estimate and will adjust the SE according to the Rubin rules. 30 Statistical significance is defined as a 2-tailed P value of <0.05
for all analyses. Analyses will be performed using SPSS version 15.0 (SPSS, Inc., Chicago, IL).
| Sample-size calculation
According to a previous study, we assumed a 45% prevalence of OSA, based on an AHI ≥15. 15 The expected adverse-event rate for untreated OSA patients with acute symptomatic PE is 20% and that for non-OSA patients is 7% within 30 days after the diagnosis of PE. Based on 80% power and a significance level of 5%, the required sample size is 215 (OSA, n = 86; non-OSA, n = 129).
Finally, with a patient loss of 5%, 15 the final sample size should be 225 patients.
| Interim analysis
According to prespecified criteria, an interim analysis will be performed after enrollment of 50% of the patients to revise sample size.
| RESULTS
As of July 31, 2017, a total of 62 patients have been recruited ( 33 In this study, the lack of association between OSA and prognosis may have been due to the absence of a confirmatory testing for the diagnosis of sleep apnea, and a lack of statistical power. In the absence of large studies that demonstrate an association between OSA and the short-term prognosis of patients with acute PE, clinical practice guidelines for the management of acute PE or OSA do not provide any recommendation on this setting. 34, 35 The POPE study will provide information on the prognostic significance of OSA diagnosis in this setting.
The findings from this study will have practical implications. A confirmation of the study hypothesis will help to explore the use of continuous positive airway pressure in normotensive patients who have acute PE and concomitant OSA. If, on the other hand, the hypothesis of POPE is rejected, patients with PE will no longer need to be exposed to an overnight sleep study, at least in the acute phase of PE.
| Study limitations
There are some limitations in the POPE trial. Sleep studies in the acute phase of PE might not reflect the real OSA status. However, one study that enrolled 15 OSA patients shortly after acute PE could not demonstrate an impact of PE on the AHI of OSA patients. 36 One weakness of the study includes the possibility of using different anticoagulant regimens after diagnosis of PE. It is not apparent whether this will affect the results.
| CONCLUSION
The POPE study is currently enrolling patients to assess the prognostic significance of untreated OSA in normotensive patients with acute PE. It is anticipated that the findings of this study will enhance our understanding of the prognosis of PE. This rigorously designed study will address the role of OSA in the initial management of patients with PE, potentially leading to better care. 
